On September 21, 2017 Juno Therapeutics, Inc. (NASDAQ:JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, reported that the pricing of its follow-on public offering of 6,100,000 shares of its common stock at a price to the public of $41.00 per share (Press release, Juno, SEP 21, 2017, View Source;p=RssLanding&cat=news&id=2302262 [SID1234520595]). In addition, Juno has granted the underwriters a 30-day option to purchase up to an additional 915,000 shares of common stock. Juno intends to use the net proceeds of the offering for general corporate purposes and working capital.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The offering is expected to close on September 26, 2017, subject to customary closing conditions. Concurrent with the completion of the follow-on public offering, Juno will complete a private placement of 659,415 shares of its common stock, at a price of $41.00 per share, to a subsidiary of Celgene Corporation. Aggregate gross proceeds from the follow-on public offering and concurrent private placement, before deducting underwriting discounts and commissions, in the case of the follow-on public offering, and expenses payable by Juno will be $277.1 million (or approximately $318.7 million if the underwriters exercise their option to purchase additional shares in full).
Morgan Stanley and J.P. Morgan are acting as joint book-running managers for the offering. Barclays and Leerink Partners are acting as co-lead managers and Wells Fargo Securities, Raymond James and Wedbush PacGrow are acting as co-managers.
A registration statement on Form S-3 relating to the common stock offered in the public offering described above was filed with the Securities and Exchange Commission (SEC) on September 20, 2017 and was automatically effective upon filing. The offering is being made only by means of a written prospectus that forms a part of the registration statement. Copies of the final prospectus related to the offering may be obtained from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014 and J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, Attn: Prospectus Department, or by telephone at (866) 803-9204.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.